We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

50 hedge funds and large institutions have $55.8M invested in aTyr Pharma in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0% more funds holding

Funds holding: 50 → 50 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

61% less capital invested

Capital invested by funds: $143M → $55.8M (-$86.8M)

Holders
50
Holders Change
–
Holders Change %
0%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
17
Reduced
16
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCM
Gruss Capital Management
New York
+$3.26M
2
RIM
RS Investment Management
California
+$2.03M
3
TCM
Tang Capital Management
California
+$1.03M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$987K
5
GPP
Great Point Partners
Connecticut
+$271K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$3.88M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.52M
3
BBA
Baker Bros. Advisors
New York
-$1.07M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$1.07M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$730K
Name Holding Trade Value Shares
Change 		Change in
Stake
RFC
26
Russell Frank Company
Washington
$105K +$145K +1,907 New
TC
27
TFS Capital
Pennsylvania
$102K +$141K +1,849 New
BIM
28
BlackRock Investment Management
Delaware
$86K +$2.43K +32 +2%
ARTA
29
A.R.T. Advisors
New York
$81K +$113K +1,481 New
UBS Group
30
UBS Group
Switzerland
$76K -$15.2K -200 -13%
TCIM
31
TIAA CREF Investment Management
New York
$76K – – –
Charles Schwab
32
Charles Schwab
California
$74K +$2.2K +29 +2%
ProShare Advisors
33
ProShare Advisors
Maryland
$71K -$9.65K -127 -9%
TD Asset Management
34
TD Asset Management
Ontario, Canada
$56K -$62.3K -820 -45%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$51K +$9.43K +124 +15%
TA
36
Teachers Advisors
New York
$35K – – –
Citigroup
37
Citigroup
New York
$31K +$15K +197 +53%
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$22K – – –
Deutsche Bank
39
Deutsche Bank
Germany
$18K +$17.5K +230 +217%
NFA
40
Nationwide Fund Advisors
Ohio
$15K – – –
AIG
41
American International Group
New York
$14K – – –
Morgan Stanley
42
Morgan Stanley
New York
$11K -$10.5K -138 -41%
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$9K +$5.78K +76 +133%
SO
44
STRS Ohio
Ohio
$7K – – –
BA
45
BlackRock Advisors
Delaware
$6K – – –
Wells Fargo
46
Wells Fargo
California
$2K +$2.43K +32 +3,200%
BJ
47
BlackRock Japan
Japan
$2K +$3.12K +41 New
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$370 -$7.6K -100 -93%
Geode Capital Management
49
Geode Capital Management
Massachusetts
$184 -$380 -5 -0.1%
Lord, Abbett & Co
50
Lord, Abbett & Co
New Jersey
– -$1.07M -7,747 Closed
1
2
3

ATYR Hedge Fund Activity: Q1 2016 in Review

50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2016, worth a combined $55.8M — down 61% from $143M a quarter earlier.

Fund positioning in ATYR was balanced in Q1 2016: 8 funds opened new positions, 8 closed out, 17 added to existing stakes and 16 trimmed.

The largest buyer was Gruss Capital Management, opening a new position worth an estimated $3.26M. The largest seller was EcoR1 Capital, cutting an estimated $3.88M.

  • 50 institutional investors held aTyr Pharma (ATYR) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $55.8M of aTyr Pharma stock for Q1 2016, down 61% quarter-over-quarter.
  • 8 funds opened new aTyr Pharma positions in Q1 2016 and 8 closed out, a net change of 0 holders.
  • The largest aTyr Pharma buyer in Q1 2016 was Gruss Capital Management, an estimated $3.26M added.
  • The largest aTyr Pharma seller in Q1 2016 was EcoR1 Capital, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2016.